Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

Exclusion Criteria

• •Multi-organ transplant that includes heart or lung recipient (participants who have their liver transplant as part of a liver-kidney dual transplant are eligible to enroll)
• •Participants with history of de novo or recurrent hepatocellular carcinoma (HCC) post-transplant and at screening
• •Histological evidence of unresolved transplant rejection
• •Current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, or other signs of decompensated cirrhosis
• •Participants meeting any of the following laboratory parameters at screening:
• •* Alanine aminotransferase (ALT) \> 10 × the upper limit of normal (ULN)
• •* International normalized ratio (INR) \> 1.5 × ULN unless the participant is stable on anticoagulant regimen affecting INR
• •* Albumin \< 3.0 g/dL
• •* Direct bilirubin ≥ 4 × ULN
• •* Platelet count \< 50,000/mL
• •Co-infection with HIV or hepatitis C virus (HCV)
• •Recent (within 4 weeks of Screening) episode or infection requiring systemic antibiotics
• •Use of any prohibited medications listed within 28 days of the Baseline/Day 1 visit
• •Significant cardiovascular, pulmonary, or neurological disease
• •Use of investigational agents within 3 months of screening, unless allowed by the Sponsor
• •Use of any prohibited medications
• •Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance
• •Known hypersensitivity to study drugs, metabolites or formulation excipients
• •Lactating females or those who may wish to become pregnant during the course of the study